Low-Dose Pioglitazone in Patients With NASH (AIM 2)

Status Recruiting

Clinical Trial Summary

To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).

Clinical Trial Description

Rationale: Several studies have shown that pioglitazone, at either 30 to 45 mg per day, is safe and effective in randomized, controlled trials (RCTs) of 6- to 24-month duration (Belfort et al, NEJM 2006; Aithal et al, Gastroenterology 2008; Sanyal et al, NEJM 2010; Cusi et al, Annals Int Med 2016; Bril et al, Diabetes Care 2019). However, pioglitazone has shown to also improve glucose and lipid metabolism at the lower dose of 15 mg per day in patients with type 2 diabetes (Aronoff et al, Diabetes Care 2000; Miyazaki et al, Diabetes Care 2002; Rosenstock et al, Int J Clin Pract. 2002; Rajagopalan et al, Diabetes Res Clin Pract 2015). However, the effect of pioglitazone at doses of 15 mg per day on liver histology in patients with steatohepatitis (NASH) has not been previously examined. Study aim: To examine the safety and efficacy of "low-dose" (15 mg/day) pioglitazone compared to placebo (control) in patients with type 2 diabetes and NASH in a 72-week randomized controlled study design. Description: This is a single center, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of pioglitazone in subjects that are 21 to 75 years of age, with nonalcoholic steatohepatitis (NASH) confirmed by liver biopsy and who have type 2 diabetes. Eligible subjects will be enrolled into two treatments arms: Pioglitazone 15 mg or placebo in a ratio 1:1. All subjects will be enrolled and followed at the our research center, the University of Florida NIH-sponsored Clinical Translational Science Institute. Upon study entry, patients will undergo a detailed medical history, physical exam, baseline routine laboratories, EKG, elastography (VCTE). Those who meet al inclusion/exclusion criteria will undergo further imaging by MRI and measurement of blood diagnostic panels hormones and biomarkers relevant to the disease state (steatohepatitis). A liver biopsy, if not done prior to study entry, will be performed. Patients that qualify (NASH with fibrosis F1-F3) will be randomized in a double-blind fashion to either pioglitazone or placebo. They will be followed during 10 scheduled visits after randomization for 72 weeks of treatment. Blood testing, imaging and a liver biopsy will be repeated as done at baseline. After completion of the study treatment period, subjects will be followed for an additional period of 4 weeks without study medication (week 76). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04501406
Study type	Interventional
Source	University of Florida
Contact	Kenneth Cusi, M.D.
Phone	3522738662
Email	kcusi@ufl.edu
Status	Recruiting
Phase	Phase 2
Start date	December 15, 2020
Completion date	August 31, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03375008` - Predictable MR Index for Nonalcoholic Steatohepatitis (NASH)	N/A
Recruiting	`NCT05979779` - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis	Phase 2
Withdrawn	`NCT02769091` - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes	Phase 2
Completed	`NCT02654977` - CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy	Phase 2
Recruiting	`NCT05211284` - Saroglitazar Magnesium 4 mg for NASH in People Living With HIV in the US	Phase 2
Completed	`NCT02421094` - Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis	Phase 2
Completed	`NCT01205087` - Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome	Phase 2
Recruiting	`NCT00152711` - Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis	N/A
Completed	`NCT02217475` - Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis	Phase 2
Completed	`NCT04031729` - Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease	Phase 1/Phase 2
Completed	`NCT03674476` - An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function	Phase 1
Recruiting	`NCT03725631` - Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD	N/A
Terminated	`NCT04565717` - A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)	Phase 1
Completed	`NCT01679197` - Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy	Phase 2
Active, not recruiting	`NCT05084404` - Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease	Phase 2
Active, not recruiting	`NCT02574325` - A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis	Phase 2
Terminated	`NCT00878592` - Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity	N/A
Recruiting	`NCT02148471` - Fatty Acids, Genes and Microbiota in Fatty Liver	N/A
Completed	`NCT00227110` - Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)	Phase 4
Completed	`NCT03656744` - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)	Phase 2